Clinical trial • Phase I • Haematology|Cardiology
ALN-F1202 for Healthy volunteer|Hereditary angioedema
Phase I trial of ALN-F1202 for Healthy volunteer|Hereditary angioedema. 56 participants.
Overview
- Trial Therapeutic Area
- Haematology|Cardiology
- Trial Disease
- Healthy volunteer|Hereditary angioedema
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 03-12-2024
- First CTIS Authorization Date
- 31-01-2025
Trial design
Phase I trial across 1 site in Belgium.
- Target Sample Size
- 56
Recruitment
- Planned Sample Size
- 56
- Recruitment Window Months
- 17
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 56
Belgium
- Earliest CTIS Part Ii Submission Date
- 24-01-2025
- Latest Decision Or Authorization Date
- 09-09-2025
- Processing Time Days
- 228
- Number Of Sites
- 1
- Number Of Participants
- 56
Sites
- Site Name
- UZ Leuven
- Department Name
- Clinical Pharmacology & Therapeutics
- Principal Investigator Name
- Jan Nelly Jozef Maria de Hoon
- Principal Investigator Email
- jan.dehoon@uz.kuleuven.ac.be
- Contact Person Name
- Jan Nelly Jozef Maria de Hoon
- Contact Person Email
- jan.dehoon@uz.kuleuven.ac.be
- Number Of Participants
- 56
Sponsor
Primary sponsor
- Full Name
- Regeneron Pharmaceuticals Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- ALN-F1202
Related trials
Other published trials that may interest you.